Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 57.55 percent increase over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $17.159 million which beat the analyst consensus estimate of $17.092 million by 0.39 percent. This is a 14.96 percent increase over sales of $14.926 million the same period last year.